Evolus Inc., a performance beauty company, has announced a partnership with Symatese to distribute Nuceiva® (botulinum toxin type A) in France. This move is part of Evolus's geographic expansion strategy, aiming to deliver its aesthetic solutions to the French market. Nuceiva®, known as Jeuveau® in the United States, has been the fastest-growing neurotoxin there for four consecutive years. The product is approved for improving the appearance of severe glabellar lines in adults below 65. The collaboration with Symatese, a well-established French firm in the aesthetics industry, will facilitate direct order and delivery of Nuceiva® to healthcare professionals in France, marking a significant step in Evolus's global growth strategy.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。